P484 Effectiveness and safety of ustekinumab in patients with Crohn’s disease: a real-world experience

Volume: 14, Issue: Supplement_1, Pages: S426 - S426
Published: Jan 1, 2020
Abstract
Background Ustekinumab is a monoclonal antibody against the p40 subunit of IL-12 and IL23 which has been proven efficacious and safe in clinical trials, yet, real-word effectiveness studies are lacking. We aimed to determine the effectiveness and safety of ustekinumab in Crohn’s disease patients in a usual care setting, as well as to identify factors that predict response to treatment. Methods This was a retrospective review of patients with...
Paper Details
Title
P484 Effectiveness and safety of ustekinumab in patients with Crohn’s disease: a real-world experience
Published Date
Jan 1, 2020
Volume
14
Issue
Supplement_1
Pages
S426 - S426
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.